Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/30/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 08/30/22 | 8-K | Current report filing |
|
   |
3 |
| 08/29/22 | UPLOAD | SEC-generated letter |
|
1 | |
| 08/23/22 | S-3 | Registration statement for specified transactions by certain issuers |
|
32 | |
| 08/17/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 08/17/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 08/17/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/15/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
202 |
| 08/05/22 | 8-K | Current report filing |
|
|
4 |
| 08/04/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 |
